Vestal Point Capital, LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1974915) · Explore on the interactive board
Vestal Point Capital, LP disclosed 68 US equity positions worth $4.3bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is BMRN at 8.1% of the reported book, followed by NBIX, ABVX. The top ten holdings are 50.3% of the book, and the portfolio behaves like about 27 equal-weight positions. Versus the prior filing it opened 11 new positions, added to 30, reduced 21 and exited 25. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Vestal Point Capital, LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 11 new, 30 added, 21 reduced, 25 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | BMRN BioMarin Pharmaceutical Inc | Healthcare | 8.1% | $344.8m | 6,025,000 | 69% | added |
| 2 | NBIX Neurocrine Biosciences Inc | Healthcare | 7.4% | $316.8m | 1,880,000 | 50% | added |
| 3 | ABVX Abivax SA | Healthcare | 7.3% | $313.1m | 2,349,443 | 57% | added |
| 4 | UTHR United Therapeutics Corp | Healthcare | 5.5% | $235.7m | 435,000 | 480% | added |
| 5 | ELVN Enliven Therapeutics Inc | Healthcare | 4.7% | $203.0m | 4,000,000 | 23% | added |
| 6 | NRIX Nurix Therapeutics Inc | Healthcare | 4.6% | $195.3m | 8,050,000 | 24% | added |
| 7 | BCAX Bicara Therapeutics Inc | Healthcare | 3.6% | $155.9m | 5,250,000 | -3% | reduced |
| 8 | TSHA Taysha Gene Therapies Inc | Healthcare | 3.1% | $132.2m | 19,415,000 | 8% | added |
| 9 | ARWR Arrowhead Pharmaceuticals Inc | Healthcare | 3.0% | $128.4m | 1,575,000 | -31% | reduced |
| 10 | ABT Abbott Laboratories | Healthcare | 3.0% | $127.0m | 1,400,000 | – | new |
| 11 | ZBH Zimmer Biomet Holdings Inc | Healthcare | 2.8% | $120.5m | 1,400,000 | 637% | added |
| 12 | IRON Disc Medicine Inc | Healthcare | 2.6% | $113.4m | 1,550,000 | 121% | added |
| 13 | GLUE Monte Rosa Therapeutics Inc | Healthcare | 2.6% | $111.3m | 4,600,000 | 28% | added |
| 14 | PODD Insulet Corp | Healthcare | 2.4% | $102.0m | 670,000 | 1224% | added |
| 15 | ASND Ascendis Pharma A/S | Healthcare | 2.3% | $100.0m | 375,000 | – | new |
| 16 | AZN AstraZeneca PLC | Healthcare | 2.0% | $85.3m | 450,000 | 350% | added |
| 17 | SNY Sanofi SA | Healthcare | 2.0% | $85.3m | 2,000,000 | 43% | added |
| 18 | RVMD Revolution Medicines Inc | Healthcare | 2.0% | $84.3m | 450,000 | -81% | reduced |
| 19 | BCRX BioCryst Pharmaceuticals Inc | Healthcare | 1.9% | $83.0m | 8,300,000 | 18% | added |
| 20 | DYN Dyne Therapeutics Inc | Healthcare | 1.8% | $75.0m | 3,375,000 | -16% | reduced |
| 21 | NKTR Nektar Therapeutics | Healthcare | 1.6% | $69.8m | 1,000,000 | 251% | added |
| 22 | GMED Globus Medical Inc | Healthcare | 1.6% | $67.2m | 850,000 | 39% | added |
| 23 | TARS Tarsus Pharmaceuticals Inc | Healthcare | 1.5% | $66.1m | 1,050,000 | 425% | added |
| 24 | IMTX Immatics NV | Healthcare | 1.5% | $62.6m | 6,175,000 | 0% | held |
| 25 | TRVI Trevi Therapeutics Inc | Healthcare | 1.4% | $57.8m | 3,100,000 | 43% | added |
| 26 | IMCR Immunocore Holdings PLC | Healthcare | 1.3% | $57.1m | 1,800,000 | -35% | reduced |
| 27 | RGEN Repligen Corp | Healthcare | 1.3% | $54.6m | 400,000 | -57% | reduced |
| 28 | BMY Bristol-Myers Squibb Co | Healthcare | 1.1% | $46.1m | 800,000 | -20% | reduced |
| 29 | uniQure NV | 1.0% | $43.1m | 935,000 | 160% | added | |
| 30 | XENE Xenon Pharmaceuticals Inc | Healthcare | 1.0% | $42.3m | 700,000 | 9% | added |
| 31 | DRUG Bright Minds Biosciences Inc | Healthcare | 0.9% | $38.3m | 545,000 | 11% | added |
| 32 | MDGL Madrigal Pharmaceuticals Inc | Healthcare | 0.8% | $34.9m | 65,000 | 107% | added |
| 33 | ALC Alcon AG | Healthcare | 0.8% | $33.5m | 500,000 | -38% | reduced |
| 34 | MYGN Myriad Genetics Inc | Healthcare | 0.8% | $32.7m | 5,735,000 | 248% | added |
| 35 | RAPP Rapport Therapeutics Inc | 0.7% | $30.4m | 730,000 | -49% | reduced | |
| 36 | CBIO Crescent Biopharma Inc | 0.7% | $29.3m | 1,630,000 | 9% | added | |
| 37 | GEHC GE HealthCare Technologies Inc | Healthcare | 0.7% | $28.8m | 450,000 | 80% | added |
| 38 | INSM Insmed Inc | Healthcare | 0.6% | $26.7m | 250,000 | – | new |
| 39 | VKTX Viking Therapeutics Inc | Healthcare | 0.6% | $26.5m | 680,000 | -26% | reduced |
| 40 | BBNX Beta Bionics Inc | Healthcare | 0.6% | $25.1m | 1,600,000 | -28% | reduced |
| 41 | REGN Regeneron Pharmaceuticals Inc | Healthcare | 0.6% | $24.9m | 40,000 | 0% | held |
| 42 | SLDB Solid Biosciences Inc | Healthcare | 0.5% | $21.6m | 2,160,000 | -57% | reduced |
| 43 | ANRO Alto Neuroscience Inc | Healthcare | 0.5% | $20.7m | 785,000 | -62% | reduced |
| 44 | TRAX First Tracks Biotherapeutics I | 0.5% | $20.4m | 1,013,000 | – | new | |
| 45 | LXEO Lexeo Therapeutics Inc | Healthcare | 0.5% | $20.1m | 4,320,000 | -3% | reduced |
| 46 | SVRA Savara Inc | Healthcare | 0.4% | $16.8m | 2,720,000 | 5% | added |
| 47 | DMRA Damora Therapeutics Inc | Healthcare | 0.3% | $15.0m | 575,000 | -4% | reduced |
| 48 | SpyGlass Pharma Inc | 0.3% | $14.9m | 670,000 | 0% | held | |
| 49 | TECX Tectonic Therapeutic Inc | Healthcare | 0.3% | $14.6m | 425,000 | 30% | added |
| 50 | AVTX Avalo Therapeutics Inc | Healthcare | 0.3% | $14.3m | 775,000 | – | new |
What did Vestal Point Capital, LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| APGE Apogee Therapeutics Inc | 10.7% | $92.6m |
| ASND Ascendis Pharma A/S | 10.0% | $85.8m |
| SRRK Scholar Rock Holding Corp | 7.6% | $65.1m |
| VERA Vera Therapeutics Inc | 6.4% | $55.0m |
| 430 Terns Pharmaceuticals Inc | 6.1% | $52.7m |
| BSX Boston Scientific Corp | 5.8% | $50.2m |
| Nuvalent Inc | 5.7% | $49.4m |
| COGT Cogent Biosciences Inc | 5.5% | $47.4m |
| CLDX Celldex Therapeutics Inc | 4.5% | $38.8m |
| 4XC1 KalVista Pharmaceuticals Inc | 4.3% | $37.2m |
| PTGX Protagonist Therapeutics Inc | 4.0% | $34.4m |
| DNLI Denali Therapeutics Inc | 4.0% | $34.0m |
| WAT Waters Corp | 3.5% | $29.8m |
| INSP Inspire Medical Systems Inc | 3.2% | $27.8m |
| SLNOEUR Soleno Therapeutics Inc | 2.8% | $24.4m |
| CYTK Cytokinetics Inc | 2.3% | $19.8m |
| WST West Pharmaceutical Services I | 2.2% | $18.8m |
| WGS GeneDx Holdings Corp | 1.9% | $16.1m |
| AGIO Agios Pharmaceuticals Inc | 1.8% | $15.2m |
| enGene Therapeutics Inc | 1.7% | $14.7m |
| ARVN Arvinas Inc | 1.1% | $9.6m |
| MPLT MapLight Therapeutics Inc | 1.0% | $8.5m |
| FULC Fulcrum Therapeutics Inc | 1.0% | $8.4m |
| CADL Candel Therapeutics Inc | 0.6% | $5.5m |
| VCYT Veracyte Inc | 0.5% | $4.2m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 94.9% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Vestal Point Capital, LP's portfolio?
Across every quarter Vestal Point Capital, LP has filed, its median largest position is 7.3% of the book and its median top-ten weight is 45.3%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 32.0 completed holding spells, the median lasted 1.0 quarters; 68.0 positions are still open and their final length is unknown.